Abliva AB (publ) (ABLI.ST) Research

Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000, focuses on developing innovative therapeutic solutions for primary mitochondrial diseases. Its pipeline includes KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions, and NV354, which is preparing for clinical studies targeting primary mitochondrial diseases specifically linked to Complex I deficiency. The company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for the treatment of traumatic brain injury. Abliva maintains strategic partnerships with entities such as Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The firm rebranded as Abliva AB (publ) in May 2020, having previously been known as NeuroVive Pharmaceutical AB (publ).

Market snapshot

Symbol
ABLI.ST
Price
$0.44
Day change
+0.23%
Market cap
$715.7M
P/E ratio
-4.91x
52-week range
0.1136-0.455
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Amniotics AB (publ) (AMNI.ST)
  • Cline Scientific AB (publ) (CLINE-B.ST)
  • CombiGene AB (publ) (COMBI.ST)
  • Cyxone AB (publ) (CYXO.ST)
  • Idogen AB (publ) (IDOGEN.ST)
  • ISR Immune System Regulation Holding AB (publ) (ISR.ST)
  • Kancera AB (publ) (KAN.ST)
  • Medivir AB (publ) (MVIR-B.ST)

Open Abliva AB (publ) (ABLI.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.